Neurent Medical is a medical device company specialising in the treatment of rhinitis.
Neurent Medical offers devices for treatment of rhinitis which includes a runny nose, sneezing, and nasal itching and congestion.
Neurent Medical was founded in 2015 by Brian Shields and David Townley. The company is originated from the BioInnovate Ireland programme at the National University of Ireland, Galway.
Neurent Medical's product offering is a minimally invasive hand-held radio-frequency device which ENT surgeons will use to treat patients in an office setting, removing the complications and costs associated with most surgical procedures.
Neurent Medical has introduced the single use device through the nostrils into the nasal cavity under direct endoscopic visualisation; where it deploys a micro electrode array that delivers targeted energy to interrupt the autonomic function within the mucosal structures of nasal cavities which will reverse the inflammatory cascade.
Neurent is backed by Atlantic Bridge, LSP, Life Sciences Fund Amsterdam, Fountain Healthcare Partners, Western Development Commission and others. The company raised €20.6M ($25M) in Series B round on Jan 20, 2021. This brings Neurent's total funding to €29.9M ($35.8M) to date.
Neurent Medical was awarded 2018 European New Product Innovation Award for developing a non-surgical, minimally invasive device that uses radio frequency (RF), by Frost & Sullivan in 2018. They were also the finalist on Irish Medtech Awards, in 2018.